AbbVie

Experts shed light on the prevalence of eye-related issues in today's digital age and dispelled common myths surrounding eye…

Market cap surged from $3.49 trillion during the first quarter (Q1) of 2023 to $3.56 trillion in Q2 2023

Lupin and AbbVie inked the licensing, development, and commercialisation agreement in 2018 for this novel oncology drug to treat…

It is expected that the prescribing patterns of Rinvoq by HCPs will follow an ongoing trend by gastroenterologists to be more…

The Association of British Pharma Industry (ABPI) said it was seeking early talks with the government to set out a new future…

The company's previous sales outlook for Skyrizi and Rinvoq in 2025 was more than $15 billion

Under the terms of the agreement, Cugene will receive an upfront payment of $48.5 million, and will also be eligible to receive…

Companies to develop additional drug candidates in immune-mediated diseases using Dragonfly's proprietary Tri-specific NK cell…

The US Food and Drug Administration (FDA) was reviewing the application for the use of Skyrizi in patients aged 16 years or older…

Skyrizi maintains a dosing regimen for PsA that is consistent with the existing regimen for moderate-to-severe plaque psoriasis…